Ikshana Therapeutics is developing treatments for age-related disease, beginning with dry age-related macular degeneration. Its research aims to restore cellular maintenance processes that decline with age and contribute to retinal damage. The company's pipeline includes CRYBA1 gene therapy and a lipocalin-2 antibody program, bringing complementary approaches to protecting vision. [1] [2]
Led by Ronjon Nag and scientific co-founder Debasish Sinha, Ikshana connects life-sciences entrepreneurship with retinal biology and gene-therapy expertise. Sinha previously held an endowed ophthalmology research chair at the University of Pittsburgh, linking the company's work to Pitt's strength in vision research. [3]